Ventyx Biosciences, Inc. is a biotechnology company based in Encinitas, California, focused on developing selective inhibitors of TYK2 for the treatment of autoimmune diseases. Incorporated in 2018, the company boasts a diverse portfolio of innovative clinical and pre-clinical programs aimed at high-value therapeutic targets. Through its research and development efforts, Ventyx is committed to advancing treatments that address unmet medical needs in the autoimmune disease space.
AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies for viral-associated diseases. Its lead product, Viralym-M, targets several viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline also includes candidates for treating respiratory syncytial virus, influenza, SARS-CoV-2, hepatitis B, and human herpesvirus-8. AlloVir's proprietary VST therapy platform aims to provide accessible treatment options for patients facing severe viral infections, addressing the pressing need for effective therapies in this area. Founded in 2013, AlloVir was previously known as ViraCyte, Inc. and rebranded in May 2019.
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response.
Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.
22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.
Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus. The Carlsbad, California-based company was established by Uri Lopatin in 2020.
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.
Ajax Therapeutics is an NYC-based biotechnology company applying computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies
Tectonic is a privately held biotechnology company that aims to transform the discovery of novel GPCR-targeted drugs and unlock the therapeutic utility the most challenging receptors in the class. Tectonic’s founders are at the forefront of scientific research in biochemistry and molecular pharmacology with an extensive track record of entrepreneurial achievement.
Notch Therapeutics Inc. is an immune cell therapy company based in Toronto, Canada, focused on developing gene-edited allogenic T cell therapies for cancer treatment. Established in 2018, the company utilizes an induced pluripotent stem cell (iPSC) platform that enables precise control of Notch signaling. This innovative technology addresses key limitations in cell therapy development by allowing for the design and manufacture of a consistent supply of therapeutic T cells. Notch Therapeutics specializes in iPSC AlloCAR therapy products aimed at treating conditions such as non-Hodgkin lymphoma, leukemia, and multiple myeloma, enabling healthcare professionals to engineer stem cells tailored to the specific biological challenges presented by complex diseases.
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, that specializes in developing vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins in a single vaccine, aiming to enhance the immune response against various infectious diseases. Affinivax focuses on a range of pathogens, including Streptococcus pneumoniae, which poses significant health risks to both children and adults. The company seeks to create vaccines that provide broader disease coverage and address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from insights provided by leading experts in infectious diseases and vaccines, and it has secured support from the Bill & Melinda Gates Foundation, along with exclusive licensing rights from Boston Children’s Hospital for its MAPS technology.
Gritstone Bio is a biotechnology company focused on developing personalized cancer immunotherapies aimed at treating various cancer types and infectious diseases. The company is advancing its lead product candidates, GRANITE and SLATE, both of which are in Phase I/II clinical trials. GRANITE targets solid tumors, including metastatic non-small cell lung cancer and gastroesophageal cancer, while SLATE serves as an off-the-shelf immunotherapy for common solid tumors and mutation-positive cancers. Gritstone is committed to identifying therapeutic neo-antigens from individual patients' tumors to create novel treatments, leveraging the expertise of its scientific founders and management team. Founded in 2015 and headquartered in Emeryville, California, the company is also engaged in strategic collaborations to enhance its research and development efforts.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead candidates, SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing Phase II trials for specific patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I trials for select advanced solid tumors. Syros employs a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to map gene regulatory circuits and modulate gene expression, positioning itself as a leader in gene control research. Additionally, Syros has established collaborations, including a target discovery agreement with Incyte Corporation focused on myeloproliferative neoplasms, and a licensing agreement with TMRC Co. Ltd. for tamibarotene's development and commercialization. Founded in 2011, Syros Pharmaceuticals aims to address significant unmet medical needs in oncology and beyond.
Cellares Corporation, founded in 2019 and based in South San Francisco, California, focuses on advancing cell therapy manufacturing for cancer treatment. The company aims to address the significant challenges associated with the production of cell therapies, which are often expensive and time-consuming due to their current one-patient-at-a-time manufacturing model. Cellares is developing The Cell Shuttle, an innovative automated and closed end-to-end manufacturing solution designed to enhance scalability and reduce costs. This system allows for the simultaneous production of multiple patient doses, increasing efficiency by tenfold compared to traditional methods. Additionally, The Cell Shuttle is expected to decrease process failure rates by three times and reduce manufacturing costs per patient by up to 70%. By integrating advanced technologies into the production process, Cellares is committed to accelerating access to life-saving therapies for patients in need.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing tissue-targeted therapeutics for cancer, chronic viral infections, and other serious diseases. The company's lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial. It is a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, specifically targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, a preclinical candidate that targets Nectin4, expressed in various cancers, and SBT8230, aimed at treating chronic hepatitis B virus infection. Utilizing its proprietary ImmunoTAC technology, Silverback aims to develop a new generation of therapies that can be systemically delivered yet act locally at disease sites, thereby modulating critical disease pathways that were previously considered inaccessible.
Neogene Therapeutics, Inc. is a biotechnology company based in New York that focuses on the development of T cell therapies to treat cancer. Founded in 2018, the company specializes in creating personalized engineered T-cells that target neo-antigens, which are mutated proteins resulting from DNA alterations in cancer cells. Neogene's innovative platform allows for the isolation of T cell receptor (TCR) genes specific to these neo-antigens from tumor biopsies, which are routinely collected from patients. By utilizing advanced DNA sequencing and genetic screening technologies, Neogene can accurately identify and engineer TCRs that enhance the ability of T-cells to detect and eliminate cancer cells. This approach aims to improve treatment outcomes for cancer patients by providing therapies tailored to their unique tumor profiles.
Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.
The company was founded in 2019 and headquartered in Alberta, Canada.
Shattuck Labs, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing innovative therapeutics for cancer and autoimmune diseases. Founded in 2016, the company leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to create dual-function fusion proteins that enhance immune responses against tumors. Its lead product candidate, SL-172154, is currently undergoing a Phase 1 clinical trial for ovarian cancer, designed to inhibit the CD47/SIRPa checkpoint interaction while activating the CD40 costimulatory receptor. Additionally, Shattuck collaborates with Takeda Pharmaceuticals on SL-279252, also in Phase 1 trials, which targets the PD-1/PD-L1 interaction and activates the OX40 receptor to improve anti-tumor immunity. Through its innovative approaches, Shattuck Labs aims to advance the field of immuno-oncology and provide effective treatments for various malignancies.
Private Equity Round in 2020
Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune-evasion. Surface is based in Cambridge, Mass.
Accent Therapeutics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing small molecule therapies for oncology through the innovative field of epitranscriptomics. Founded in 2017, the company explores post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting RNA-modifying proteins associated with cancer, Accent Therapeutics aims to translate advanced scientific research into effective treatments for patients, ultimately providing new therapeutic options in the fight against cancer.
ElevateBio, LLC, based in Cambridge, Massachusetts, is a holding company focused on the development of cell and gene-based therapies. Established in 2017, ElevateBio operates a portfolio of subsidiary companies that aim to create innovative treatments for cancer and viral infections. The company partners with leading scientists and inventors to foster its portfolio and has established a centralized facility designed to streamline the translation of research and development into commercially viable therapies. This integrated approach enables the efficient development, manufacturing, and commercialization of life-transforming medicines, ultimately helping to provide patients with effective treatments for severe diseases.
Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing anticalin-based therapeutics. Anticalins are low molecular-weight proteins derived from lipocalins, which are naturally occurring proteins in the human body. The company’s lead respiratory candidate, PRS-060, is in Phase I trials for asthma and other inflammatory diseases, while its lead immuno-oncology candidate, PRS-343, is also in Phase I trials targeting various cancers. Additionally, Pieris is advancing PRS-080, a treatment for functional iron deficiency in patients with chronic kidney disease, currently in Phase IIa trials, and PRS-344, a bispecific anticalin-antibody fusion protein in preclinical development for oncology. The company collaborates with several partners, including Les Laboratoires Servier, AstraZeneca, and Seattle Genetics, and has research collaborations with academic institutions such as the University of Pittsburgh. Founded in 2000, Pieris Pharmaceuticals aims to address critical medical needs through its innovative drug development approach.
AlloVir, Inc. is a clinical-stage cell therapy company based in Cambridge, Massachusetts, specializing in the development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies for viral-associated diseases. Its lead product, Viralym-M, targets several viruses including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. The company's pipeline also includes candidates for treating respiratory syncytial virus, influenza, SARS-CoV-2, hepatitis B, and human herpesvirus-8. AlloVir's proprietary VST therapy platform aims to provide accessible treatment options for patients facing severe viral infections, addressing the pressing need for effective therapies in this area. Founded in 2013, AlloVir was previously known as ViraCyte, Inc. and rebranded in May 2019.
ElevateBio, LLC, based in Cambridge, Massachusetts, is a holding company focused on the development of cell and gene-based therapies. Established in 2017, ElevateBio operates a portfolio of subsidiary companies that aim to create innovative treatments for cancer and viral infections. The company partners with leading scientists and inventors to foster its portfolio and has established a centralized facility designed to streamline the translation of research and development into commercially viable therapies. This integrated approach enables the efficient development, manufacturing, and commercialization of life-transforming medicines, ultimately helping to provide patients with effective treatments for severe diseases.
Prevail Therapeutics Inc. is a biotechnology company based in New York that specializes in developing gene therapies for neurodegenerative diseases. Founded in 2017 with support from The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, the company is focused on creating innovative adeno-associated virus (AAV)-based treatments. Its lead candidate, PR001, is currently undergoing Phase I/II clinical trials aimed at treating Parkinson's disease linked to GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is developing PR006 for frontotemporal dementia associated with GRN mutations and PR004 for various synucleinopathies. The company is dedicated to advancing therapies that can modify the course of these debilitating conditions.
Ashvattha Therapeutics, Inc. is a pharmaceutical company focused on developing innovative products for neurology, ophthalmology, and inflammation-related conditions. Established in 2015 and headquartered in Redwood City, California, with research facilities in Baltimore, Maryland, the company aims to create therapeutics that precisely target human diseases. This approach is designed to minimize off-target toxicity, systemic side effects, and immunogenicity often associated with other treatment platforms. Ashvattha Therapeutics has developed a diverse pipeline of nine therapeutics that span the fields of neurology, oncology, and ophthalmology, reflecting its commitment to advancing targeted treatment options for patients.
Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for neurological diseases. Founded in 2018 and based in New York, the company employs adeno-associated virus (AAV) technology to create treatments for conditions such as Charcot-Marie Tooth disease (CMT4J), Aspartylglucosaminuria (AGU), and various lysosomal storage diseases. Neurogene aims to improve patient outcomes by providing effective gene therapies for rare neurological disorders that currently lack viable treatment options. Through its innovative approaches, the company seeks to enhance the quality of life for patients and their families affected by these debilitating conditions.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
Avidity Biosciences is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disorder. The company's development pipeline also includes programs focused on treating various muscle diseases, such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Additionally, Avidity is exploring therapeutic applications for immune and other cell types, leveraging its proprietary AOC platform to reach previously undruggable tissues and effectively target the genetic underpinnings of these conditions. Founded in 2012, Avidity Biosciences is headquartered in La Jolla, California.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumors. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, which demonstrates a unique mechanism of action and targets derived from antibodies identified through Atreca's innovative discovery platform. ATRC-101 has shown in vitro reactivity with a significant majority of cancer samples, including those from ovarian, non-small cell lung, colorectal, and breast cancer patients. Additionally, the company has established a strategic research collaboration with Merck Sharp & Dohme Corp. to identify antigenic targets of select antibodies with potential applications in oncology. Founded in 2010, Atreca aims to advance its therapies to improve treatment options for cancer patients.
Accent Therapeutics, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, focused on developing small molecule therapies for oncology through the innovative field of epitranscriptomics. Founded in 2017, the company explores post-transcriptional chemical modifications of RNA, which play a crucial role in regulating proteins essential for cellular growth and differentiation. By precisely targeting RNA-modifying proteins associated with cancer, Accent Therapeutics aims to translate advanced scientific research into effective treatments for patients, ultimately providing new therapeutic options in the fight against cancer.
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
Omniox is a biopharmaceutical company focused on developing innovative treatments for hypoxic diseases, which occur when tissues receive insufficient oxygen. This condition is linked to serious health issues, including various cancers and cardiovascular diseases. The company utilizes a proprietary protein-based platform technology known as H-NOX, which is designed to deliver oxygen and nitric oxide directly to hypoxic tissues. By specifically targeting these areas, Omniox aims to restore normal tissue function, potentially improving patient outcomes and offering new therapeutic options. Through its work, Omniox seeks to advance oxygen-based therapies that address the challenges posed by diseases associated with low oxygen levels.
Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.
Prevail Therapeutics Inc. is a biotechnology company based in New York that specializes in developing gene therapies for neurodegenerative diseases. Founded in 2017 with support from The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, the company is focused on creating innovative adeno-associated virus (AAV)-based treatments. Its lead candidate, PR001, is currently undergoing Phase I/II clinical trials aimed at treating Parkinson's disease linked to GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is developing PR006 for frontotemporal dementia associated with GRN mutations and PR004 for various synucleinopathies. The company is dedicated to advancing therapies that can modify the course of these debilitating conditions.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development.
The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases.
The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.
Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.
Intellia Therapeutics is a genome editing company based in Cambridge, Massachusetts, focused on developing curative gene-editing treatments using the CRISPR/Cas9 technology. The company aims to address severe and life-threatening genetic diseases through both in vivo and ex vivo therapeutic approaches. Its pipeline includes programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Additionally, Intellia is developing engineered cell therapies for oncological and autoimmune diseases. The company has established collaborations with various entities, including leading pharmaceutical firms and research institutions, to enhance its research and development efforts. Founded in 2014, Intellia Therapeutics holds a comprehensive intellectual property platform for the therapeutic application of CRISPR technology, positioning it at the forefront of gene editing innovation.
Clementia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Montreal, Canada, focused on developing innovative treatments for patients with ultra-rare bone disorders and other diseases characterized by high unmet medical needs. Founded in 2010, the company specializes in disease-modifying therapies, with its lead product candidate being palovarotene, an oral small molecule. Palovarotene has demonstrated significant potential in preventing abnormal bone formation and fibrosis across various tissues. The candidate is currently undergoing evaluation in the Phase III MOVE trial, targeting conditions such as fibrodysplasia ossificans progressive and multiple osteochondromas, as well as dry eye disease. Clementia's commitment to addressing debilitating health issues highlights its role in advancing treatment options for affected patients.
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development.
The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases.
The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.
Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.
Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.